[go: up one dir, main page]

SG11201704597WA - Agonistic tnf receptor binding agents - Google Patents

Agonistic tnf receptor binding agents

Info

Publication number
SG11201704597WA
SG11201704597WA SG11201704597WA SG11201704597WA SG11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA SG 11201704597W A SG11201704597W A SG 11201704597WA
Authority
SG
Singapore
Prior art keywords
receptor binding
binding agents
tnf receptor
agonistic
agonistic tnf
Prior art date
Application number
SG11201704597WA
Inventor
Ugur Sahin
Friederike Gieseke
Isil Altintas
David Satijn
Paul Parren
Original Assignee
Biontech Ag
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, Genmab As filed Critical Biontech Ag
Publication of SG11201704597WA publication Critical patent/SG11201704597WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
SG11201704597WA 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents SG11201704597WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015050255 2015-01-08
PCT/EP2016/050308 WO2016110584A1 (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents

Publications (1)

Publication Number Publication Date
SG11201704597WA true SG11201704597WA (en) 2017-07-28

Family

ID=55072677

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201704597WA SG11201704597WA (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents
SG10202003171TA SG10202003171TA (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202003171TA SG10202003171TA (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents

Country Status (25)

Country Link
US (4) US10457735B2 (en)
EP (3) EP4071176A3 (en)
JP (4) JP6744326B2 (en)
KR (2) KR102640769B1 (en)
CN (3) CN109476761B (en)
AU (2) AU2016205974B2 (en)
BR (1) BR112017013189B1 (en)
CA (2) CA3224830A1 (en)
CY (2) CY1122399T1 (en)
DK (2) DK3242890T3 (en)
ES (2) ES2755527T3 (en)
HR (2) HRP20220811T1 (en)
HU (2) HUE059219T2 (en)
LT (1) LT3623386T (en)
ME (1) ME03576B (en)
MX (3) MX377773B (en)
PL (2) PL3242890T3 (en)
PT (2) PT3242890T (en)
RS (2) RS63384B1 (en)
RU (1) RU2723131C2 (en)
SG (2) SG11201704597WA (en)
SI (2) SI3623386T1 (en)
SM (2) SMT202200288T1 (en)
WO (1) WO2016110584A1 (en)
ZA (1) ZA201704797B (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
SI2943511T1 (en) 2013-01-14 2020-01-31 Xencor, Inc. Novel heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG11201607983YA (en) 2014-03-28 2016-10-28 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353409B2 (en) 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
JP7058219B2 (en) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Heterodimer antibody that binds to CD3 and PSMA
KR20180107102A (en) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 Identification of new antigens, manufacture, and uses
DK3445788T3 (en) 2016-04-22 2022-04-11 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
MA45255A (en) 2016-06-14 2019-04-17 Xencor Inc BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
JP7138630B2 (en) * 2016-07-14 2022-09-16 ゲンマブ エー／エス Multispecific antibodies against CD40 and CD137
IL265046B2 (en) * 2016-08-30 2025-04-01 Xencor Inc Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL311603A (en) * 2016-09-23 2024-05-01 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
JP7256744B2 (en) 2017-01-20 2023-04-12 マジェンタ セラピューティクス インコーポレイテッド Compositions and methods for depletion of CD137+ cells
JP2020511959A (en) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー Humanized anti-CD40 antibody
MX2020000583A (en) 2017-07-20 2020-09-10 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods.
CN116333131A (en) * 2017-08-04 2023-06-27 健玛保 Binding agents that bind to PD-L1 and CD137 and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
JP7164596B2 (en) * 2017-08-28 2022-11-01 システィミューン， インク． ANTI-CD3 ANTIBODY AND METHODS OF PRODUCTION AND USE THEREOF
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing epitope binding presentation for neoantigens
KR102722731B1 (en) 2017-12-19 2024-10-25 젠코어 인코포레이티드 Engineered IL-2 FC fusion protein
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
KR20210003814A (en) 2018-04-18 2021-01-12 젠코어 인코포레이티드 TIM-3 targeting heterodimer fusion protein containing IL-15/IL-15Rα Fc-fusion protein and TIM-3 antigen binding domain
MX2020010910A (en) 2018-04-18 2021-02-09 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof.
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
TWI861005B (en) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 Antibody molecules that bind pd-l1 and cd137
JP7612571B2 (en) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド IL-12 heterodimer FC-fusion protein
WO2020094744A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
BR112022015151A2 (en) 2020-02-04 2022-12-20 Genmab As METHOD FOR REDUCING OR PREVENTING PROGRESSION OF A TUMOR OR TREATING CANCER, AND, COMPOSITION
EP4574971A2 (en) * 2020-03-31 2025-06-25 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US20230400471A1 (en) * 2020-10-15 2023-12-14 Bioincept, Llc Systems, compositions and methods of determining viability of embryos using the same
CN112175080B (en) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 Human interleukin-6 resistant high affinity rabbit monoclonal antibody and application
WO2022122765A2 (en) 2020-12-07 2022-06-16 Genmab A/S Antibody and taxane combination therapy
CA3211334A1 (en) * 2021-03-09 2022-09-15 Yali FU Multispecific binding agents against cd40 and cd137 in therapy
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
EP4320147A4 (en) 2021-04-08 2025-06-18 Marengo Therapeutics, Inc. MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES
WO2022268740A1 (en) 2021-06-21 2022-12-29 Genmab A/S Combination dosage regime of cd137 and pd-l1 binding agents
WO2024050318A1 (en) * 2022-08-27 2024-03-07 H. Lee Moffitt Cancer Center And Research Institute Cd40l 41bbl bispecific proteins
US20240400703A1 (en) 2023-05-12 2024-12-05 Genmab A/S Antibodies capable of binding to ox40, variants thereof and uses thereof
CN117069848B (en) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 Anti-human CD146 rabbit monoclonal antibody and its application
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
CN118440198B (en) * 2024-04-03 2024-11-15 武汉爱博泰克生物科技有限公司 Anti-human CD69 protein rabbit monoclonal antibody and application thereof
CN118620078B (en) * 2024-07-09 2024-11-19 武汉爱博泰克生物科技有限公司 Antibodies against human CD45RA protein, antibody conjugates and their applications
CN118453854B (en) * 2024-07-12 2024-10-29 广州粤华制药有限公司 Composition for establishing chronic glomerulonephropathy model and application thereof
CN119431591A (en) * 2024-12-16 2025-02-14 无锡傲锐东源生物科技有限公司 Monoclonal antibody against human PSP protein and its application

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2005511627A (en) * 2001-11-20 2005-04-28 シアトル ジェネティクス，インコーポレーテッド Treatment of immunological diseases using anti-CD30 antibodies
CN101023102B (en) * 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 anti-OX40L antibody
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
JP2010518873A (en) 2007-02-27 2010-06-03 ジェネンテック， インコーポレイテッド Antagonist anti-OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
JP5681482B2 (en) 2007-03-29 2015-03-11 ゲンマブ エー／エス Bispecific antibody and method for producing the same
ES2573458T3 (en) * 2007-09-14 2016-06-08 Vrije Universiteit Brussel Improvement of the stimulatory capacity of the T cells of cells presenting human antigen and their use in vaccination
CA2949772A1 (en) * 2007-12-14 2009-06-25 Pfizer Inc. Binding molecules to the human ox40 receptor
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
JP5782385B2 (en) 2009-02-17 2015-09-24 ユーシービー ファーマ ソシエテ アノニム Antibody molecule having specificity for human OX40
WO2012004367A1 (en) 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
JP5828909B2 (en) * 2011-01-10 2015-12-09 シーティー アトランティック リミテッド Combination therapy including tumor-associated antigen-binding antibody
PE20142243A1 (en) 2011-07-11 2015-01-11 Glenmark Pharmaceuticals Sa ANTIBODIES THAT BIND OX40 AND ITS USES
RU2562874C1 (en) * 2011-08-23 2015-09-10 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Antibodies against ox40 and methods of their application
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AU2014238546C1 (en) * 2013-03-18 2019-01-17 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
TW201619200A (en) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
JP7138630B2 (en) * 2016-07-14 2022-09-16 ゲンマブ エー／エス Multispecific antibodies against CD40 and CD137

Also Published As

Publication number Publication date
KR20210041634A (en) 2021-04-15
RU2723131C2 (en) 2020-06-08
MX377773B (en) 2025-03-11
CA3224830A1 (en) 2016-07-14
PL3623386T3 (en) 2022-08-08
US20210253725A1 (en) 2021-08-19
AU2016205974B2 (en) 2021-11-04
DK3242890T3 (en) 2019-10-21
WO2016110584A1 (en) 2016-07-14
HRP20191824T1 (en) 2020-01-24
MX2017008917A (en) 2018-02-09
EP4071176A3 (en) 2022-12-14
PL3242890T3 (en) 2020-04-30
SI3242890T1 (en) 2020-01-31
MX2020012240A (en) 2021-02-22
CY1125349T1 (en) 2025-05-09
EP3242890B1 (en) 2019-09-04
SMT201900702T1 (en) 2020-01-14
KR20170132717A (en) 2017-12-04
JP6950056B2 (en) 2021-10-13
AU2016205974A1 (en) 2017-07-13
US10457735B2 (en) 2019-10-29
DK3623386T3 (en) 2022-07-04
BR112017013189B1 (en) 2024-03-05
CN109476761A (en) 2019-03-15
US20180194849A1 (en) 2018-07-12
US10927181B2 (en) 2021-02-23
JP7487376B2 (en) 2024-05-20
ES2922398T3 (en) 2022-09-14
CN111499752B (en) 2024-05-31
RU2020115901A (en) 2020-08-05
EP3623386B1 (en) 2022-04-13
BR112017013189A2 (en) 2018-04-10
CN117843799A (en) 2024-04-09
CY1122399T1 (en) 2020-11-25
CA2969888A1 (en) 2016-07-14
SMT202200288T1 (en) 2022-09-14
ZA201704797B (en) 2019-05-29
US11814411B2 (en) 2023-11-14
LT3623386T (en) 2022-08-10
CN111499752A (en) 2020-08-07
HUE048532T2 (en) 2020-07-28
RU2017127792A (en) 2019-02-08
CN109476761B (en) 2020-01-10
EP4071176A2 (en) 2022-10-12
AU2022200571B2 (en) 2024-11-21
HUE059219T2 (en) 2022-10-28
SI3623386T1 (en) 2022-09-30
JP6744326B2 (en) 2020-08-19
ME03576B (en) 2020-07-20
MX2024012093A (en) 2024-11-08
JP2022025064A (en) 2022-02-09
US20240254249A1 (en) 2024-08-01
US20200079866A1 (en) 2020-03-12
SG10202003171TA (en) 2020-05-28
ES2755527T3 (en) 2020-04-22
JP2023085435A (en) 2023-06-20
KR102238326B1 (en) 2021-04-12
JP2018506298A (en) 2018-03-08
PT3242890T (en) 2019-12-10
EP3242890A1 (en) 2017-11-15
NZ733157A (en) 2021-10-29
KR102640769B1 (en) 2024-02-27
JP2020188797A (en) 2020-11-26
EP3623386A1 (en) 2020-03-18
RU2017127792A3 (en) 2019-06-17
HRP20220811T1 (en) 2022-09-30
PT3623386T (en) 2022-07-18
AU2022200571A1 (en) 2022-02-17
RS59693B1 (en) 2020-01-31
RS63384B1 (en) 2022-08-31
JP7390345B2 (en) 2023-12-01
KR20240028548A (en) 2024-03-05

Similar Documents

Publication Publication Date Title
ZA201704797B (en) Agonistic tnf receptor binding agents
ZA201802371B (en) Glucagon receptor agonists
ZA201704818B (en) Agonistic icos binding proteins
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
IL259269A (en) Improved tnf binders
GB201702617D0 (en) Receptor
IL272798A (en) Agonistic tnf receptor binding agents
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
GB201713296D0 (en) Binding agents
GB201701351D0 (en) Binding agents